1987
DOI: 10.1083/jcb.104.6.1603
|View full text |Cite
|
Sign up to set email alerts
|

Nonneuronal cells mediate neurotrophic action of vasoactive intestinal peptide.

Abstract: Abstract. The developmental regulation of neuronal survival by vasoactive intestinal peptide (VIP) was investigated in dissociated spinal cord-dorsal root ganglion (SC-DRG) cultures. Previous studies demonstrated that VIP increased neuronal survival in SC-DRG cultures when synaptic transmission was blocked with tetrodotoxin (TTX). This effect was further investigated to determine if VIP acted directly on neurons or via nonneuronal cells. For these studies, SC-DRG cells were cultured under conditions designed t… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

3
76
0
1

Year Published

1988
1988
2022
2022

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 202 publications
(80 citation statements)
references
References 27 publications
(24 reference statements)
3
76
0
1
Order By: Relevance
“…The expression of VIP-selective high-affinity binding sites in glial cells (Brenneman et al, 1987;Gozes et al, 1991), in the human glioma cell line U-343 Mgcl 2:6 (Nielsen et al, 1990), and in the human glioblastoma XF-498L (Fabry et al, 2000) has been reported previously, and it has been demonstrated that the neuroprotective effects of VIP or PACAP could be observed for very low concentrations, close to the femtomolar range (Kong et al, 1999;Offen et al, 2000). However, data from the present studies are, as far as we know, an unprecedented characterization of VIP-selective binding sites with such a very high affinity, in the femtomolar range.…”
Section: Journal Of Molecular Neuroscience Volume 21 2003mentioning
confidence: 99%
“…The expression of VIP-selective high-affinity binding sites in glial cells (Brenneman et al, 1987;Gozes et al, 1991), in the human glioma cell line U-343 Mgcl 2:6 (Nielsen et al, 1990), and in the human glioblastoma XF-498L (Fabry et al, 2000) has been reported previously, and it has been demonstrated that the neuroprotective effects of VIP or PACAP could be observed for very low concentrations, close to the femtomolar range (Kong et al, 1999;Offen et al, 2000). However, data from the present studies are, as far as we know, an unprecedented characterization of VIP-selective binding sites with such a very high affinity, in the femtomolar range.…”
Section: Journal Of Molecular Neuroscience Volume 21 2003mentioning
confidence: 99%
“…2-wk old astroglial (17, 39) cultures (confluent 75-cm 2 flasks) were washed three times with PBS and conditioned medium was collected (10 ml PBS/flask) during a 3-h incubation with 0.1 nM VIP (an amount previously shown to be optimal for releasing neurotrophic activity from astroglial cells, references 18,19). The medium was centrifuged (3,000 g for 10 min) and dialyzed (3.5-kD cutoff) against 50 mM sodium phosphate buffer, pH 7.0, 4 Њ C. Neuroprotection was assayed initially in tetrodotoxin-blocked spinal cord cultures.…”
Section: Methodsmentioning
confidence: 99%
“…The ADNF secretagogue, VIP, has been shown to prevent neurotoxicity associated with the HIV envelope protein (GP120, reference 22) as well as against neurotoxicity associated with the beta amyloid peptide which is deposited in the brains of Alzheimer's disease patients (23). The mechanisms of these VIP effects are probably due to its ability to promote the secretion of neuroprotective substances from glial cells (18)(19)(20)(21). Here, we test the hypothesis that VIP's neuroprotective actions are mediated in part through ADNF.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…contre des atteintes trĂšs variĂ©es incluant l'excitotoxicitĂ© par les analogues du glutamate et la toxicitĂ© de la protĂ©ine d'enveloppe gp120 du VIH. Brenneman avait toutefois observĂ© il y a dix ans que cet effet du VIP n'Ă©tait pas direct et passait obligatoirement par la stimulation d'astrocytes [2]. Un certain nombre de facteurs neuroprotecteurs peuvent ĂȘtre produits par les astrocytes mais un paramĂštre troublait les auteurs : l'activitĂ© neurotrophique pouvait ĂȘtre obtenue Ă  l'aide de milieu conditionnĂ© astrocytaire extrĂȘmement diluĂ©, trop pour que des facteurs « classiques » puissent ĂȘtre impliquĂ©s.…”
unclassified